Herba Leonuri, also named Chinese Motherwort, has been extensively investigated as an effective agent on the uterus system. Our group has been studying the natural products of Herba Leonuri for several years, and during this period, many biological activities of the drug were recognized. Leonurine (4-guanidino-N-butyl-syringate) is an alkaloid present in Herba Leonuri. Recently, growing evidence has highlighted the therapeutic potential of leonurine in multiple diseases, especially cardiovascular. In this review, we discuss the biological activities of leonurine, as well as recent advances involving this alkaloid.
ZhuR.F., NiS.D., WangX.S. (2005) Study on new synthetic process for leonurine. Journal of Anhui University (Natural Science Edition), 29, 84–86 (in Chinese).
2.
ZhuY.Z., ZhuY.C., GolkeP., UngerT. (1998) Overview on pharmacological properties of angiotensin converting enzyme inhibitors. ACE inhibition and target organ protection. Euromed Communications, Oxford, 1–20.
3.
LiuX.H., XinH., HouA.J., ZhuY.Z. (2009) Protective effects of leonurine in neonatal rat hypoxic cardiomyocytes and rat infarcted heart. Clinical and Experimental Pharmacology and Physiology, 36, 696–703.
4.
XinH., LiuX.H., ZhuY.Z. (2009) Herba leonurine attenuates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells. European Journal of Pharmacology, 612, 75–79.
5.
LiuX-h, ChenP-f, PanL-l, De SilvaR., ZhuY-z. (2009) 4-Guanidino-n-butyl syringate (leonurine, SCM 198) protects H9c2 rat ventricular cells from hypoxia-induced apoptosis. Journal of Cardiovascular Pharmacology, 54, 437–444.
6.
Hua LiuX., Long PanL., Hai GongQ., Zhun ZhuY. (2010) Antiapoptotic effect of novel compound from Herba leonuri-leonurine (SCM-198): a mechanism through inhibition of mitochondria dysfunction in H9c2 cells. Current Pharmaceutical Biotechnology, 11, 895–905.
LiuX., PanL., GongQ., ZhuY. (2010) Leonurine (SCM-198) improves cardiac recovery in rat during chronic infarction. European Journal of Pharmacology, 649, 236–241.
9.
XinH., GuM., WangW.W., HuangS.Y., LiF.P., CaiH., ZhuY.Z., ZhangX.M. (2012) Effects of leonurine on L-type calcium channel in rat ventricular myocytes. Biological and Pharmaceutical Bulletin, 35, 1249–1256.
10.
LiuC., GuX., ZhuY.Z. (2010) Synthesis and biological evaluation of novel leonurine–SPRC conjugate as cardioprotective agents. Bioorganic & Medicinal Chemistry Letters, 20, 6942–6946.
11.
LiuC., GuoW., ShiX., KaiumM.A., GuX., ZhuY.Z. (2011) Leonurine-cysteine analog conjugates as a new class of multifunctional anti-myocardial ischemia agent. European Journal of Medicinal Chemistry, 46, 3996–4009.
12.
EpsteinF.H., RossR. (1999) Atherosclerosis—an inflammatory disease. New England Journal of Medicine, 340, 115–126.
13.
HulsmansM., HolvoetP. (2010) The vicious circle between oxidative stress and inflammation in atherosclerosis. Journal of Cellular and Molecular Medicine, 14, 70–78.
14.
KutukO., BasagaH. (2003) Inflammation meets oxidation: NF-κB as a mediator of initial lesion development in atherosclerosis. Trends in Molecular Medicine, 9, 549–557.
15.
ZhangY., GuoW., WenY., XiongQ., LiuH., WuJ., ZouY., ZhuY. (2012) SCM-198 attenuates early atherosclerotic lesions in hypercholesterolemic rabbits via modulation of the inflammatory and oxidative stress pathways. Atherosclerosis, 224, 43–50.
16.
PangS., TsuchiyaS., HorieS., UchidaM., MurayamaT., WatanabeK. (2001) Enhancement of phenylephrine-induced contraction in the isolated rat aorta with endothelium by H2O-extract from an Oriental medicinal plant Leonuri herba. The Japanese Journal of Pharmacology, 86, 215–222.
17.
ChenC-X, KwanC-Y. (2001) Endothelium-independent vasorelaxation by leonurine, a plant alkaloid purified from Chinese motherwort. Life Sciences, 68, 953–960.
18.
DonnanG.A., FisherM., MacleodM., DavisS.M. (2008) Stroke. The Lancet, 371, 1612–1623.
19.
WardlawJ.M., WarlowC.P., CounsellC. (1997) Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. The Lancet, 350, 607–614.
20.
LohK.P., QiJ., TanB.K.H., LiuX.H., WeiB.G., ZhuY.Z. (2010) Leonurine protects middle cerebral artery occluded rats through antioxidant effect and regulation of mitochondrial function. Stroke, 41, 2661–2668.
21.
QiJ., HongZ.Y., XinH., ZhuY.Z. (2010) Neuroprotective effects of leonurine on ischemia/reperfusion-induced mitochondrial dysfunctions in rat cerebral cortex. Biological and Pharmaceutical Bulletin, 33, 1958–1964.
22.
LiuH., ZhangX., DuY., JiH., LiS., LiL., XingY., ZhangX., DongL., WangC. (2012) Leonurine protects brain injury by increased activities of UCP4, SOD, CAT and Bcl-2, decreased levels of MDA and Bax, and ameliorated ultrastructure of mitochondria in experimental stroke. Brain Research, 1474, 73–81.
23.
Fernandez-EspejoE. (2004) Pathogenesis of Parkinson's disease. Molecular Neurobiology, 29, 15–30.
24.
SchulzJ.B. (2005) Neuronal pathology in Parkinson's disease. Cell and Tissue Research, 320, 211–211.
25.
UttaraB., SinghA.V., ZamboniP., MahajanR.T. (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology, 7, 65–74.
26.
SayreL.M., PerryG., SmithM.A. (2007) Oxidative stress and neurotoxicity. Chemical Research in Toxicology, 21, 172–188.
27.
FukuiH., MoraesC.T. (2008) The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?Trends in Neurosciences, 31, 251–256.
28.
ShiX.R., HongZ.Y., LiuH.R., ZhangY.C., ZhuY.Z. (2011) Neuroprotective effects of SCM198 on 6-hydroxydopamine-induced behavioral deficit in rats and cytotoxicity in neuronal SH-SY5Y cells. Neurochemistry International, 58, 851–860.
BlaskoI., Stampfer-KountchevM., RobatscherP., VeerhuisR., EikelenboomP., Grubeck-LoebensteinB. (2004) How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell, 3, 169–176.
31.
Wyss-CorayT. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response?Nature Medicine, 12, 1005–1015.
32.
MandrekarS., LandrethG.E. (2010) Microglia and inflammation in Alzheimer's disease. CNS & Neurological Disorders Drug Targets, 9, 156–67.
33.
HongZ-Y, ShiX-R, ZhuK., WuT-T, ZhuY-Z. (2014) SCM-198 inhibits microglial overactivation and attenuates Aβ(1-40)-induced cognitive impairments in rats via JNK and NF-κB pathways. Journal of Neuroinflammation, 11, 147–162.
34.
WildS., RoglicG., GreenA., SicreeR., KingH. (2004) Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047–1053.
35.
WarrenR.E. (2004) The stepwise approach to the management of type 2 diabetes. Diabetes Research and Clinical Practice, 65, S3–S8.
36.
PatelS., SantaniD. (2009) Role of NF-κB in the pathogenesis of diabetes and its associated complications. Pharmacological Reports, 61, 595–603.
37.
HuangH., XinH., LiuX., XuY., WenD., ZhangY., ZhuY.Z. (2012) Novel anti-diabetic effect of SCM-198 via inhibiting the hepatic NF-κB pathway in db/db mice. Bioscience Reports, 32, 185–195.
38.
JhaV., Garcia-GarciaG., IsekiK., LiZ., NaickerS., PlattnerB., SaranR., WangAY-M, YangC-W. (2013) Chronic kidney disease: global dimension and perspectives. The Lancet, 382, 260–272.
39.
HydeG.D., TaylorR.F., AshtonN., BorlandS.J., WuH.S.G., GilmoreA.P., CanfieldA.E. (2014) Axl tyrosine kinase protects against tubulo-interstitial apoptosis and progression of renal failure in a murine model of chronic kidney disease and hyperphosphataemia. PloS one, 9, e102096.
40.
DuffieldJ.S. (2014) Cellular and molecular mechanisms in kidney fibrosis. The Journal of Clinical Investigation, 124, 2299–2306.
41.
AndersH-J, RyuM. (2011) Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney International, 80, 915–925.
42.
ChengH., BoY., ShenW., TanJ., JiaZ., XuC., LiF. (2015) Leonurine ameliorates kidney fibrosis via suppressing TGF-β and NF-κB signaling pathway in UUO mice. International Immunopharmacology, 25, 406–415.
43.
SingbartlK., KellumJ.A. (2012) AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney International, 81, 819–825.
44.
ChawlaL.S., KellumJ.A. (2012) Acute kidney injury in 2011: biomarkers are transforming our understanding of AKI. Nature reviews Nephrology, 8, 68–70.
45.
MatejovicM., ChvojkaJ., RadejJ., LedvinovaL., KarvunidisT., KrouzeckyA., NovakI. (2011) Sepsis and acute kidney injury are bidirectional. Contribution to Nephrology, 174, 78–88.
46.
MayeuxP.R. (1997) Pathobiology of lipopolysaccharide. Journal of Toxicology and Environmental Health, 51, 415–435.
47.
ZarjouA., AgarwalA. (2011) Sepsis and acute kidney injury. Journal of the American Society of Nephrology, 22, 999–1006.
KongY., YeungH., CheungY., PhilM., HwangJ., ChanY., LawY., NgK., YeungC. (1976) Isolation of the uterotonic principle from Leonurus artemisia, the Chinese motherwort. The American Journal of Chinese Medicine, 4, 373–382.
50.
YeungH., KongY., LayW., ChengK. (1977) Structure and biological effect of leonurine: a uterotonic principle from the Chinese drug, I mu Ts’ ao. Plant Medica, 31, 51–56.
51.
ChenZ., ChenC., KwanC. (2000) Leonurine, an alkaloid from Leonurus artemesia, induces contraction in mouse uterine smooth muscle but relaxation in vascular smooth muscle of rat portal vein. Biomedical Research, 11, 209–212.
52.
LiX., YuanF-L, ZhaoY-Q, LuW-G, LiC-W, HeC-H. (2013) Effect of leonurine hydrochloride on endothelin and the endothelin receptor-mediated signal pathway in medically-induced incomplete abortion in rats. European Journal of Obstetrics & Gynecology and Reproductive Biology, 169, 299–303.
53.
LeungP.C., SiuW.S. (2013) Herbal treatment for osteoporosis: a current review. Journal of Traditional and Complementary Medicine, 3, 82–87.
54.
LiC., YangZ., LiZ., MaY., ZhangL., ZhengC., QiuW., WuX., WangX., LiH. (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Journal of Bone and Mineral Research, 26, 644–656.
55.
YuanF-L, XuR-S, JiangD-L, HeX-L, SuQ., JinC., LiX. (2015) Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways. Bone, 75, 128–137.
56.
ViguierC., AroraS., GilmartinN., WelbeckK., O'KennedyR. (2009) Mastitis detection: current trends and future perspectives. Trends in Biotechnology, 27, 486–493.
57.
SongX., WangT., ZhangZ., JiangH., WangW., CaoY., ZhangN. (2015) Leonurine exerts anti-inflammatory effect by regulating inflammatory signaling pathways and cytokines in lps-induced mouse mastitis. Inflammation, 38, 79–88.
58.
ZhuY., HuangS., TanB., SunJ., WhitemanM., ZhuY-C. (2004) Antioxidants in Chinese herbal medicines: a biochemical perspective. Natural Product Reports, 21, 478–489.
59.
WangZ., ZhangP-L, JuY. (2004) Effect of leonurine on the activity of creatine kinase. Journal of Asian Natural Products Research, 6, 281–287.
60.
WojtyniakK., SzymańskiM., MatławskaI. (2013) Leonurus cardiaca L. (motherwort): a review of its phytochemistry and pharmacology. Phytotherapy Research, 27, 1115–1120.
61.
LiuX-H, XinH., ZhuY. (2007) More than a “mother-benefiting” herb: cardioprotective effect of Herba leonuri. Sheng li xue bao:[Acta physiologica Sinica], 59, 578–584.
62.
LiuX., PanL., WangX., GongQ., ZhuY.Z. (2012) Leonurine protects against tumor necrosis factor-α-mediated inflammation in human umbilical vein endothelial cells. Atherosclerosis, 222, 34–42.
